Review summary
Teaching objective: Diagnosis and six-month treatment of drug-susceptible cavitary pulmonary tuberculosis in a 21-year-old dentist under the ATS/CDC/IDSA guideline (three sputum smears, nucleic acid amplification, culture and susceptibility, HIV and hepatitis testing, baseline liver tests and vision checks, isoniazid, rifampin, pyrazinamide, and ethambutol for eight weeks then isoniazid and rifampin for eighteen weeks by video-observed therapy, stopping ethambutol on susceptibility results, monthly liver and symptom monitoring, release from isolation, two-month culture conversion, contact investigation, and public-health reporting), together with care for an alcohol use disorder that raises the risk of isoniazid liver injury (AUDIT, brief intervention, counseling, and a structured safety assessment with the 988 Suicide & Crisis Lifeline), and an honest account of a liver-monitoring gap.
Historical timeline
| Date | Event | Claims |
|---|---|---|
| August 14, 1851 | Born in Griffin, Georgia. | CLM-0001 |
| 1866 | His mother died of tuberculosis. | CLM-0002 |
| 1872 | Graduated from the Pennsylvania College of Dental Surgery and began practicing dentistry in Atlanta. | CLM-0003 |
| 1873 | Diagnosed with tuberculosis and advised to move to a drier climate. | CLM-0004, CLM-0005 |
| September 1873 | Arrived in Dallas, Texas. | CLM-0005 |
| November 8, 1887 | Died of tuberculosis in Glenwood Springs, Colorado. | CLM-0007 |
Evidence claims
D = documented, R = retrospective, S = synthetic.
| Grade | Claim | Certainty | Sources |
|---|---|---|---|
| D | John Henry Holliday was born on August 14, 1851, in Griffin, Georgia. | confirmed | John Henry "Doc" Holliday (1851-1887) supports |
| D | In 1866 Holliday's mother died of tuberculosis. Family history of pulmonary tuberculosis. |
confirmed | John Henry "Doc" Holliday (1851-1887) supports |
| D | He enrolled at the Pennsylvania College of Dental Surgery in 1870 and graduated in 1872, then practiced dentistry in Atlanta before opening his own practice in Griffin. Supports his occupation as a newly qualified dentist in the modern episode. |
confirmed | John Henry "Doc" Holliday (1851-1887) supports Doc Holliday dies of tuberculosis supports |
| D | Shortly after beginning his career as a dentist in Atlanta he developed a bad cough; doctors diagnosed tuberculosis and advised a move to a more arid climate. He developed chronic pulmonary tuberculosis. Anchor for the modern pulmonary tuberculosis. |
confirmed | Doc Holliday dies of tuberculosis supports John Henry "Doc" Holliday (1851-1887) supports |
| D | He was diagnosed with tuberculosis in 1873 and moved west for a healthier, drier climate, arriving in Dallas, Texas, in September 1873. Dates the diagnosis; the episode's true frame ends before the move. |
confirmed | Holliday, Doc (1852-1887) supports John Henry "Doc" Holliday (1851-1887) supports |
| D | He made his living at the card tables, aggravating his tuberculosis with heavy drinking and late nights. Anchor for the modern alcohol use disorder; the source does not date the heavy drinking. |
confirmed | Doc Holliday dies of tuberculosis supports |
| D | He died of tuberculosis in its final stages on November 8, 1887, in Glenwood Springs, Colorado, at the age of 36. Recorded as a fact; the modern episode ends with cure. |
confirmed | John Henry "Doc" Holliday (1851-1887) supports Holliday, Doc (1852-1887) supports Doc Holliday dies of tuberculosis supports |
Modern synthetic problem list
| Grade | Problem | Clinical status | Verification | Placement | Historical claims |
|---|---|---|---|---|---|
| S | Pulmonary tuberculosis, right upper lobe cavitary, sputum smear-positive, confirmed by nucleic acid amplification without rifampin resistance | active | confirmed | both_with_link | CLM-0004, CLM-0005 |
| S | Alcohol use disorder, mild, with binge drinking | active | confirmed | both_with_link | CLM-0006 |
| S | Acute viral gastroenteritis during tuberculosis treatment, with a mild aminotransferase rise below the threshold for drug-induced liver injury; resolved | resolved | confirmed | active |
Synthetic outcome measures
| Grade | Date | Measure | Result | Coding |
|---|---|---|---|---|
| S | 2026-02-10 | Hemoglobin [Mass/volume] in Blood | 12.6 g/dL (low) Reference 13.2-16.6 g/dL |
http://loinc.org · 718-7 |
| S | 2026-02-10 | Leukocytes [#/volume] in Blood by Automated count | 9.4 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 2026-02-10 | Platelets [#/volume] in Blood by Automated count | 412 10*3/uL (high) Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 2026-02-10 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 34 U/L Reference 7-56 U/L |
http://loinc.org · 1742-6 |
| S | 2026-02-10 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 38 U/L Reference 10-40 U/L |
http://loinc.org · 1920-8 |
| S | 2026-02-10 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.6 mg/dL Reference 0.1-1.2 mg/dL |
http://loinc.org · 1975-2 |
| S | 2026-02-10 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 92 U/L Reference 40-129 U/L |
http://loinc.org · 6768-6 |
| S | 2026-02-10 | Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma | 78 U/L (high) Reference 8-61 U/L |
http://loinc.org · 2324-2 |
| S | 2026-02-10 | Albumin [Mass/volume] in Serum or Plasma | 3.4 g/dL (low) Reference 3.5-5 g/dL |
http://loinc.org · 1751-7 |
| S | 2026-02-10 | Creatinine [Mass/volume] in Serum or Plasma | 0.86 mg/dL Reference 0.74-1.35 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-02-10 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 124 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-02-10 | Glucose [Mass/volume] in Serum or Plasma | 90 mg/dL Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 2026-02-10 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.2% Reference <=5.6% |
http://loinc.org · 4548-4 |
| S | 2026-02-10 | Visual acuity uncorrected Right eye by ETDRS eye chart | 85 Reference >=80 |
http://loinc.org · 79878-5 |
| S | 2026-02-10 | Visual acuity uncorrected Left eye by ETDRS eye chart | 85 Reference >=80 |
http://loinc.org · 79879-3 |
| S | 2026-02-10 | Total score [AUDIT] | 15 | http://loinc.org · 75624-7 |
| S | 2026-02-10 | Total score [AUDIT-C] | 9 | http://loinc.org · 75626-2 |
| S | 2026-02-10 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | http://loinc.org · 44261-6 |
| S | 2026-02-24 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 41 U/L Reference 7-56 U/L |
http://loinc.org · 1742-6 |
| S | 2026-02-24 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 39 U/L Reference 10-40 U/L |
http://loinc.org · 1920-8 |
| S | 2026-02-24 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.7 mg/dL Reference 0.1-1.2 mg/dL |
http://loinc.org · 1975-2 |
| S | 2026-02-24 | Visual acuity uncorrected Right eye by ETDRS eye chart | 85 Reference >=80 |
http://loinc.org · 79878-5 |
| S | 2026-02-24 | Visual acuity uncorrected Left eye by ETDRS eye chart | 84 Reference >=80 |
http://loinc.org · 79879-3 |
| S | 2026-02-24 | Total score [AUDIT-C] | 4 | http://loinc.org · 75626-2 |
| S | 2026-03-17 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 52 U/L Reference 7-56 U/L |
http://loinc.org · 1742-6 |
| S | 2026-03-17 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 47 U/L (high) Reference 10-40 U/L |
http://loinc.org · 1920-8 |
| S | 2026-03-17 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.8 mg/dL Reference 0.1-1.2 mg/dL |
http://loinc.org · 1975-2 |
| S | 2026-03-17 | Total score [AUDIT-C] | 2 | http://loinc.org · 75626-2 |
| S | 2026-04-14 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 38 U/L Reference 7-56 U/L |
http://loinc.org · 1742-6 |
| S | 2026-04-14 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 35 U/L Reference 10-40 U/L |
http://loinc.org · 1920-8 |
| S | 2026-04-14 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.7 mg/dL Reference 0.1-1.2 mg/dL |
http://loinc.org · 1975-2 |
| S | 2026-04-14 | Total score [AUDIT-C] | 1 | http://loinc.org · 75626-2 |
| S | 2026-08-18 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 30 U/L Reference 7-56 U/L |
http://loinc.org · 1742-6 |
| S | 2026-08-18 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 28 U/L Reference 10-40 U/L |
http://loinc.org · 1920-8 |
| S | 2026-08-18 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.6 mg/dL Reference 0.1-1.2 mg/dL |
http://loinc.org · 1975-2 |
| S | 2026-08-18 | Hemoglobin [Mass/volume] in Blood | 14.4 g/dL Reference 13.2-16.6 g/dL |
http://loinc.org · 718-7 |
| S | 2026-08-18 | Total score [AUDIT-C] | 3 | http://loinc.org · 75626-2 |
| S | 2026-08-18 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | http://loinc.org · 44261-6 |
| S | 2026-05-19 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 64 U/L (high) Reference 7-56 U/L |
http://loinc.org · 1742-6 |
| S | 2026-05-19 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 58 U/L (high) Reference 10-40 U/L |
http://loinc.org · 1920-8 |
| S | 2026-05-19 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.9 mg/dL Reference 0.1-1.2 mg/dL |
http://loinc.org · 1975-2 |
| S | 2026-05-19 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 98 U/L Reference 40-129 U/L |
http://loinc.org · 6768-6 |
| S | 2026-05-19 | Total score [AUDIT-C] | 4 | http://loinc.org · 75626-2 |
| S | 2026-09-22 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | http://loinc.org · 55758-7 |
| S | 2026-09-22 | Total score [AUDIT-C] | 3 | http://loinc.org · 75626-2 |
Synthetic vital signs
| Date | Measure | Result | LOINC | Grade |
|---|---|---|---|---|
| 2026-02-10 | Body height | 178 cm | 8302-2 | S |
| 2026-02-10 | Body weight | 58 kg | 29463-7 | S |
| 2026-02-10 | Body mass index (BMI) [Ratio] | 18.3 kg/m2 | 39156-5 | S |
| 2026-02-10 | Systolic blood pressure | 112 mm[Hg] | 8480-6 | S |
| 2026-02-10 | Diastolic blood pressure | 70 mm[Hg] | 8462-4 | S |
| 2026-02-10 | Heart rate | 104 /min | 8867-4 | S |
| 2026-02-10 | Respiratory rate | 20 /min | 9279-1 | S |
| 2026-02-10 | Body temperature | 37.8 Cel | 8310-5 | S |
| 2026-02-10 | Oxygen saturation in Arterial blood by Pulse oximetry | 95 % | 59408-5 | S |
| 2026-02-24 | Body height | 178 cm | 8302-2 | S |
| 2026-02-24 | Body weight | 59 kg | 29463-7 | S |
| 2026-02-24 | Body mass index (BMI) [Ratio] | 18.6 kg/m2 | 39156-5 | S |
| 2026-02-24 | Systolic blood pressure | 114 mm[Hg] | 8480-6 | S |
| 2026-02-24 | Diastolic blood pressure | 72 mm[Hg] | 8462-4 | S |
| 2026-02-24 | Heart rate | 92 /min | 8867-4 | S |
| 2026-02-24 | Respiratory rate | 18 /min | 9279-1 | S |
| 2026-02-24 | Body temperature | 37.3 Cel | 8310-5 | S |
| 2026-02-24 | Oxygen saturation in Arterial blood by Pulse oximetry | 96 % | 59408-5 | S |
| 2026-03-17 | Body height | 178 cm | 8302-2 | S |
| 2026-03-17 | Body weight | 61 kg | 29463-7 | S |
| 2026-03-17 | Body mass index (BMI) [Ratio] | 19.3 kg/m2 | 39156-5 | S |
| 2026-03-17 | Systolic blood pressure | 116 mm[Hg] | 8480-6 | S |
| 2026-03-17 | Diastolic blood pressure | 72 mm[Hg] | 8462-4 | S |
| 2026-03-17 | Heart rate | 84 /min | 8867-4 | S |
| 2026-03-17 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-03-17 | Body temperature | 36.8 Cel | 8310-5 | S |
| 2026-03-17 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 % | 59408-5 | S |
| 2026-04-14 | Body height | 178 cm | 8302-2 | S |
| 2026-04-14 | Body weight | 62.5 kg | 29463-7 | S |
| 2026-04-14 | Body mass index (BMI) [Ratio] | 19.7 kg/m2 | 39156-5 | S |
| 2026-04-14 | Systolic blood pressure | 116 mm[Hg] | 8480-6 | S |
| 2026-04-14 | Diastolic blood pressure | 74 mm[Hg] | 8462-4 | S |
| 2026-04-14 | Heart rate | 78 /min | 8867-4 | S |
| 2026-04-14 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-04-14 | Body temperature | 36.7 Cel | 8310-5 | S |
| 2026-04-14 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2026-08-18 | Body height | 178 cm | 8302-2 | S |
| 2026-08-18 | Body weight | 65.5 kg | 29463-7 | S |
| 2026-08-18 | Body mass index (BMI) [Ratio] | 20.7 kg/m2 | 39156-5 | S |
| 2026-08-18 | Systolic blood pressure | 118 mm[Hg] | 8480-6 | S |
| 2026-08-18 | Diastolic blood pressure | 74 mm[Hg] | 8462-4 | S |
| 2026-08-18 | Heart rate | 72 /min | 8867-4 | S |
| 2026-08-18 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-08-18 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-08-18 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2026-05-19 | Body height | 178 cm | 8302-2 | S |
| 2026-05-19 | Body weight | 61.8 kg | 29463-7 | S |
| 2026-05-19 | Body mass index (BMI) [Ratio] | 19.5 kg/m2 | 39156-5 | S |
| 2026-05-19 | Systolic blood pressure | 108 mm[Hg] | 8480-6 | S |
| 2026-05-19 | Diastolic blood pressure | 68 mm[Hg] | 8462-4 | S |
| 2026-05-19 | Heart rate | 98 /min | 8867-4 | S |
| 2026-05-19 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-05-19 | Body temperature | 37.4 Cel | 8310-5 | S |
| 2026-05-19 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2026-09-22 | Body height | 178 cm | 8302-2 | S |
| 2026-09-22 | Body weight | 66 kg | 29463-7 | S |
| 2026-09-22 | Body mass index (BMI) [Ratio] | 20.8 kg/m2 | 39156-5 | S |
| 2026-09-22 | Systolic blood pressure | 118 mm[Hg] | 8480-6 | S |
| 2026-09-22 | Diastolic blood pressure | 72 mm[Hg] | 8462-4 | S |
| 2026-09-22 | Heart rate | 68 /min | 8867-4 | S |
| 2026-09-22 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-09-22 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-09-22 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
Social, functional, and mental status
Social history
- S Newly qualified dentist in his first year of practice, an associate in a group dental office; works close to patients' faces
- S Shares an apartment with one roommate; no children in the household; no one in the home with a weakened immune system
- S Alcohol: whiskey four or more evenings a week, often six or more drinks, mostly at card games late at night; AUDIT 15. Meets three criteria for alcohol use disorder in the past year
- S Plays poker for money several nights a week; up late most nights
- S No tobacco or other drug use; no travel outside the country; no incarceration or homelessness
Functional status
- S Independent; working full days until the cough and night sweats wore him down over the last month
Mental status
- S Alert, sharp, and dryly humorous; organized thought; no signs of intoxication or withdrawal
- S Mood worried about his work and his health; PHQ-9 6; no thoughts of suicide or self-harm
Structured safety assessment
This assessment is synthetic and does not convert historical behavior into a present-day fact.
Allergies and medications
Allergies
- S No known allergy
Medications
- S Isoniazid 300 mg tablet, one tablet daily
- S Rifampin 300 mg capsules, two capsules (600 mg) daily
- S Pyrazinamide 500 mg tablets, three tablets (1500 mg) daily
- S Ethambutol 400 mg tablets, three tablets (1200 mg) daily
- S Vitamin B6 (pyridoxine) 50 mg tablet, one tablet daily
Procedures and immunizations
Procedures
- S Chest X-ray, two views: right upper lobe consolidation with a 3 cm thick-walled cavity; no effusion or hilar enlargement
- S Chest X-ray, two views, at the end of treatment: cavity closed, with residual right upper lobe scarring; kept as the baseline for any future comparison
Immunizations
- S 2022-08-30: Tetanus, diphtheria, and pertussis (Tdap) booster
- S 2026-09-22: Influenza vaccine, 2026-2027 season
- S 2026-09-22: Hepatitis B vaccine (HepB-CpG), dose 1 of 2
Past medical history
True biography with historical dates; not part of the synthetic care timeline.
- D 1872: Developed a bad cough shortly after beginning to practice dentistry (CLM-0004)
Family history
- D mother: Pulmonary tuberculosis; died of it in 1866
Care-plan goals
| Goal | Target date | Status | Outcome |
|---|---|---|---|
| Complete 182 doses of treatment under video-observed therapy within six months | 2026-08-18 | completed | All 182 doses completed: 56 in the intensive phase and 126 in the continuation phase, with one dose held during a stomach illness and made up at the end |
| Sputum culture negative at two months | 2026-08-18 | completed | Two-month culture showed no growth, so the continuation phase stayed at four months |
| No alcohol during treatment, to protect his liver | 2026-08-18 | active | Not fully met: no drinking for most of the six months, with one evening of heavy drinking at a party about three months into treatment; AUDIT-C 3 at the end |
| Return to work once he is no longer infectious | 2026-03-17 | completed | Released from home isolation after three negative sputum smears and back at work four weeks into treatment |
| Weight back to at least 64 kg by the end of treatment | 2026-08-18 | completed | 65.5 kg at the end of treatment, from 58.0 kg at diagnosis |
Interventions
| Intervention | Status | Guideline |
|---|---|---|
| Infectious diseases consultation to confirm the regimen and plan monitoring for cavitary pulmonary tuberculosis in a man who drinks heavily | completed | GL-ATS-TB-2016, GL-ATS-TB-2025 |
| Standard treatment: isoniazid, rifampin, pyrazinamide, and ethambutol for eight weeks, then isoniazid and rifampin for eighteen weeks, by video-observed therapy with the health department, with pyridoxine | completed | GL-ATS-TB-2016 |
| Monitoring: monthly symptom and weight check, sputum smear and culture monthly until two consecutive cultures are negative, liver tests at two weeks and monthly because of alcohol, and vision checks while on ethambutol | completed | GL-ATS-TB-2016, GL-ATS-HEPATOTOX-2006 |
| Public health: same-day report to the local health department, home isolation until noninfectious, and a contact investigation of his household, coworkers, and patients led by the health department | completed | GL-CDC-CONTACT-2005, GL-ATS-TB-2016 |
| Alcohol care: brief intervention at diagnosis, a goal of no alcohol during treatment, counseling with a substance-use counselor, medication offered, AUDIT-C at each visit, and a safety review with the 988 Suicide & Crisis Lifeline at every visit | completed | GL-USPSTF-ALC-2018, GL-SUD-2021, GL-SUICIDE-2024 |
Planned encounters
- 2026-02-10 — Diagnosis of cavitary pulmonary tuberculosis: sputum, chest X-ray, baseline tests, public-health report, home isolation, and alcohol assessment with a safety assessment (ENC-001)
- 2026-02-24 — Two-week follow-up on treatment with infectious diseases consultation (ENC-002)
- 2026-03-17 — Five-week review: susceptibility results, release from isolation, and liver monitoring (ENC-003)
- 2026-04-14 — End of the intensive phase: two-month sputum and the start of the continuation phase (ENC-004)
- 2026-05-19 — Same-day sick visit for nausea and vomiting during tuberculosis treatment (ENC-006, unscheduled)
- 2026-08-18 — End-of-treatment review after six months (ENC-005)
- 2026-09-22 — Adult preventive visit (ENC-007)
Supporting documents
- History and physical
- Progress note 01
- Progress note 02 — Focused Visit (Follow-up)
- Progress note 03 — Focused Visit (Follow-up)
- Progress note 04 — Focused Visit (Follow-up)
- Progress note 05 — Sick Visit
- Progress note 06 — Focused Visit (Care-plan review)
- Progress note 07 — Preventive Visit
- Infectious Diseases referral
- Infectious Diseases consultation
- Patient care plan
- Teaching note
- Provenance CSV
C-CDA note documents
Each link opens a readable copy; the XML beside it is the exchange file.
- History and physical (XML)
- Progress note 01 (XML)
- Progress note 02 — Focused Visit (Follow-up) (XML)
- Progress note 03 — Focused Visit (Follow-up) (XML)
- Progress note 04 — Focused Visit (Follow-up) (XML)
- Progress note 05 — Sick Visit (XML)
- Progress note 06 — Focused Visit (Care-plan review) (XML)
- Progress note 07 — Preventive Visit (XML)
- Infectious Diseases referral (XML)
- Infectious Diseases consultation (XML)
Sources
| ID | Source | Publisher | Type |
|---|---|---|---|
| SRC-0001 | John Henry "Doc" Holliday (1851-1887) | New Georgia Encyclopedia (Georgia Humanities) | scholarly |
| SRC-0002 | Holliday, Doc (1852-1887) | Encyclopedia of the Great Plains (University of Nebraska-Lincoln) | scholarly |
| SRC-0003 | Doc Holliday dies of tuberculosis | HISTORY.com (A&E Television Networks) | other |
| SRC-0004 | HISTMED Master Roster v3 | The Human Record project | other |
Review status
| Review | Status | Notes |
|---|---|---|
| schema validation | not_started | Run scripts/build.ps1 -Conformance. |
| clinical review | not_started | Awaiting clinician review. |
| provenance review | not_started | Biographical facts from the New Georgia Encyclopedia, the Encyclopedia of the Great Plains, and HISTORY.com. The birth year conflict (1851 or 1852) is recorded. The heavy drinking is documented but undated; its placement at the time of diagnosis is synthetic. |
| safe messaging review | not_started | Alcohol claims are marked sensitive; the safety assessment records no current risk and gives the 988 Suicide & Crisis Lifeline; no contact is named; death recorded without detail. |
Comments and corrections
Sign in with GitHub to comment on this record. To report a specific error, ideally with a source, use the feedback form; each report becomes a tracked issue.
Comments appear on the online version of this page.